Capital World Investors 13D and 13G filings for Revance Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-10-07 10:08 am Sale |
2024-10-07 | 13G | Revance Therapeutics, Inc. RVNC |
Capital World Investors | 0 0.000% |
-6,948,769 (Position Closed) |
Filing |
| 2024-09-09 10:40 am Sale |
2024-09-09 | 13G | Revance Therapeutics, Inc. RVNC |
Capital World Investors | 6,948,769 6.600% |
-4,990,307 (-41.80%) |
Filing |
| 2024-02-09 6:21 pm Purchase |
2024-02-07 | 13G | Revance Therapeutics, Inc. RVNC |
Capital World Investors | 11,939,076 13.600% |
2,458,920 (+25.94%) |
Filing |
| 2023-02-13 2:49 pm Purchase |
2023-02-14 | 13G | Revance Therapeutics, Inc. RVNC |
Capital World Investors | 9,480,156 11.500% |
1,016,247 (+12.01%) |
Filing |
| 2022-12-09 1:58 pm Purchase |
2022-12-12 | 13G | Revance Therapeutics, Inc. RVNC |
Capital World Investors | 8,463,909 10.300% |
4,751,909 (+128.01%) |
Filing |
| 2022-02-11 3:31 pm Purchase |
2022-02-14 | 13G | Revance Therapeutics, Inc. RVNC |
Capital World Investors | 3,712,000 5.200% |
3,712,000 (New Position) |
Filing |